Find clinical trials | Bayside Health (Alfred)

PWI in enduring PVI

Outcomes of redo atrial fibrillation ablation with posterior wall isolation in patients with enduring pulmonary vein isolation (Trial Not Registered)

To determine the effectiveness of posterior wall isolation in patients presenting for redo atrial fibrillation (AF) ablation with enduring pulmonary vein isolation (PVI).

Currently recruiting

QUANTUM-WILD

Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial Of Quizartinib Administered in Combination With Induction and Consolidation Chemotherapy and Administered as Maintenance Therapy in Adult Patients With Newly Diagnosed FLT3-ITD Negative Acute Myeloid Leukemia

About the QuANTUM-Wild Study: QuANTUM-Wild is a clinical trial for people who are newly diagnosed with acute myeloid leukaemia (AML) that is FLT3-ITD–negative. The purpose of the clinical trial is to evaluate an oral study drug called quizartinib—to see if it may improve this type of AML and is safe. This study drug is currently not approved for this condition, which is why it’s being evaluated. Everyone in the clinical trial will also receive the standard chemotherapy for their type of AML. This clinical trial will not delay the start of chemotherapy. Your study doctor may recommend that you receive a stem cell transplant. If so, your study doctor will be able to provide you with more information about this procedure. Although it is not part of this clinical trial, you may be able to continue participating in the clinical trial after you receive a stem cell transplant.

Currently recruiting

R3767-ONC-2011

A Phase 3 Trial of Fianlimab (REGN3767, anti-Lag-3) + Cemiplimab versus Pembrolizumab in Patients with Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma (NCT05352672)

No longer recruiting

R3767-ONC-2055

A Phase 3 Trial of Fianlimab (anti-LAG-3) and Cemiplimab versus Pembrolizumab in the Adjuvant Setting in Patients with Completely Resected High-risk Melanoma (NCT05608291)

No longer recruiting

R3ACT-R

A randomised trial of most closely HLA-matched third-party donor-derived virus-specific cytotoxic T-lymphocytes in patients with untreated viral infection post-allogeneic stem cell transplantation (R3ACT Randomised (R3R)) (ACTRN12620000171910p)

Currently recruiting

R5458-ONC-2246

A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma [LINKER-MM5] (NCT07222761)

A study to compare linvoseltamab monotherapy and linvoseltamab + carfilzomib combination therapy with standard-of-care combination regimens in participants with relapsed/refractory multiple myeloma (RRMM).

Currently recruiting

Rainbow Trial [RAY902CT]

PHASE IB OPEN LABEL BASKET TRIAL OF RAY121 TO INHIBIT CLASSICAL COMPLEMENT PATHWAY IN IMMUNOLOGICAL DISEASES [RAINBOW TRIAL] (NCT06371417)

The RAY902CT study is designed to evaluate the safety and efficacy of RAY121 in adult participants with Bullous Pemphigoid (BP) or Behcet’s syndrome. Participants receive trial medication via a monthly injection under the skin (subcutaneous). The treatment period will be approximately 12 weeks with the option of a long-term extension.

Currently recruiting

RAPID STUDY

A multi-centre, pRospective, safety and efficacy evaluation study on Automated external defibrillation in PatIents with CellAED (ACTRN12621000258853)

No longer recruiting

RAPiD-I Study

First In Human Feasibility Clinical Study Evaluating the Safety of the XPD System for Periosteal Distraction [PD] (ACTRN12625000159459)

Chronic, non-healing foot and leg ulcers are often a result of reduced blood flow due to Peripheral Artery Disease (PAD) or other ischemic (reduced blood flow) conditions in patients with chronic diseases, such as diabetes. These ulcers can compromise quality of life and increase the risk of serious infection and result in injury and death of the tissue. The XPD is a new device that is designed to stretch the soft tissue around the bone (called the periosteum) to trigger the body’s natural healing process. It moves in a slow, controlled way to support healing and new tissue growth.

Currently recruiting

RASolve 301

RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 versus Docetaxel in Patients with Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC (NCT06881784)

Global, open-label, Phase 3 study, patients with locally advanced or metastatic RAS-mutant NSCLC will be randomized to RMC-6236 or docetaxel (in a 1:1 ratio) on a 21-day treatment cycle.

Currently recruiting

RATIONALISE

RATIONALISE - Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension (TRU-RLS-21) (ACTRN12622000359730)

Currently recruiting

REBUILD-SM

A Randomised Clinical Trial of a digital Self-Management package for people with Interstitial Lung Disease (ACTRN12623001133628)

Currently recruiting

ReCAPS

Recovery-focused Community support to Avoid readmissions and improve participation after Stroke (ACTRN12618001468213)

Currently recruiting

REDEEM

REDEEM: A randomised controlled trial of VV ECMO to de-sedate, extubate, and mobilise in hypoxic respiratory failure. (NCT05562505)

Currently recruiting

ReDiscover-2 RLY-2608-102

A Phase 3 Open-label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative [HR+/HER2-] Locally Advanced or Metastatic Breast Cancer Following Recurrence or Progression On or After Treatment with a CDK4/6 Inhibitor (NCT06982521)

This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutation following recurrence or progression on or after treatment with a CDK4/6 inhibitor.

Currently recruiting

REFORM

Reducing the frequency of outpatient review in people with cystic fibrosis on high-efficacy modulator therapy – a non-inferiority, randomised controlled trial (REFORM) (ACTRN12624000696594)

Currently recruiting

Regeneron

A First-In-Human (FIH) Phase 1/2 Study To Assess Safety, Tolerability, And Preliminary Anti-Tumor Activity Of REGN7945, An Anti-CD38 x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody, In Combination With Linvoseltamab, An Anti-BCMA x Anti-CD3 Bispecific Monoclonal Antibody, In Participants With Relapsed/Refractory Multiple Myeloma. (NCT06669247)

Currently recruiting

RELATIVITY-127

A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed dose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastatic or Unresectable Melanoma (NCT05625399)

No longer recruiting

REMAP_CAP

Randomized,Embedded,Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) (NCT02735707)

Currently recruiting

ReMATCH

Repeat Ablation of Persistent Atrial Fibrillation, including Mitral Isthmus and Cavo-Tricuspid Isthmus Ablations, with the FARAPULSE Pulsed Field Ablation System (NCT06735534)

The FARAPULSE Pulsed Field Ablation System used in this study is comprised of two medical devices called the FARAWAVE and FARAPOINT. FARAWAVE and FARAPONT are both different types of catheters that use pulsed electrical energy to treat abnormal heart rhythms. The study is looking at how safe and effective these two medical devices are when used to treat a heart condition called persistent atrial fibrillation (PersAF) after a failed initial ablation procedure.

Currently recruiting